Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Garza

Plastic and Reconstructive Surgery Nashville, TN Medical Doctor

NPI 1841406063 CMS profile 356325

2400 Patterson St Ste 204, Nashville, TN 37203

Open in the dashboard

General payments

$5,568

126 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Garza of Nashville, TN is reported in the CMS Open Payments database as having received $5,568 across 126 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,297 12
2024 General $597 18
2023 General $570 13
2022 General $449 15
2021 General $538 19
2020 General $705 28
2019 General $411 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Garza
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Robert Garza were reported at $2,297. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Robert Garza Plastic and Reconstructive Surgery median Middle half National median
2019 $411 $335 $121–$1,264 $163
2020 $705 $162 $57–$417 $114
2021 $538 $245 $89–$735 $132
2022 $449 $325 $120–$932 $149
2023 $570 $343 $129–$999 $160
2024 $597 $390 $141–$1,085 $164
2025 $2,297 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aziyo Biologics, Inc. $1,558 5 payments
  2. Smith+Nephew, Inc. $1,081 69 payments
  3. AbbVie, Inc. $536 15 payments
  4. Integra LifeSciences Corporation $389 4 payments
  5. Biocomposites Inc $345 4 payments
  6. Sientra, Inc. $314 6 payments
  7. Allergan Inc. $309 4 payments
  8. PolyNovo North America LLC $288 5 payments
  9. Musculoskeletal Transplant Foundation Inc. $186 3 payments
  10. Merz North America, Inc. $165 2 payments
  11. Other $396 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,174 124 payments
  2. Honoraria $1,068 1 payment
  3. Long term medical supply or device loan $326 1 payment
Products named General payments · program years 2019–2025
  1. ECM Patch,Pouch $1,558 5 payments
  2. OASIS $604 22 payments
  3. NATRELLE SALINE-FILLED BREAST IMPLANTS $536 15 payments
  4. STRAVIX Extremities & Limb Restoration $518 14 payments
  5. GRAFIX PL $360 10 payments
  6. DuraSorb Monofilament Mesh $356 2 payments
  7. Stimulan $345 4 payments
  8. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $314 6 payments
  9. GRAFIX $210 7 payments
  10. STRAVIX Extremities & Limb Restoration $184 8 payments
  11. Other $1,425 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

70

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$439

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

77.1%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 39 $278
Cephalexin Generic 16 $114
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $47

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$221,483

Medicare's payments for the services billed

Medicare patients

150

Average age 71

Services billed

728

91 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Ischemic heart disease 39%
Depression 38%
Diabetes 36%
Chronic kidney disease 36%
Atrial fibrillation 26%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record